Keros Therapeutics, Inc. (KROS) compared with its closest peers (SION, WHWK, ORGO, NERV, RNA). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $238.27M | -21.9 |
| Whitehawk Therapeutics Inc (WHWK) | $233.91M | -7.3 |
| Organogenesis Holdings Inc. (ORGO) | $231.61M | 34.5 |
| Minerva Neurosciences, Inc. (NERV) | $230.14M | -0.1 |
| Avidity Biosciences, Inc. (RNA) | $226.39M | -14.5 |
| Immunic, Inc. (IMUX) | $225.00M | -0.9 |
| AN2 Therapeutics, Inc. (ANTX) | $218.87M | -1.0 |
| SIGA Technologies, Inc. (SIGA) | $218.76M | 10.8 |
| PepGen Inc. (PEPG) | $216.78M | -3.1 |
| Journey Medical Corporation (DERM) | $213.21M | -16.4 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
KROS overview · KROS earnings · KROS financials · KROS KPIs · KROS investor relations · KROS ownership · KROS filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.